Studies of retroviral infection in humanized mice

Virology

Volumn 479-480, Issue , 2015, Pages 297-309

  Marsden, Matthew D ^a   Zack, Jerome A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Animal models; Gene therapy; HIV; HTLV; Humanized mice; Latency; Pathogenesis; SCID mouse

Indexed keywords

ANIMAL; DISEASE MODEL; GROWTH, DEVELOPMENT AND AGING; HOST PATHOGEN INTERACTION; HUMAN; PATHOGENICITY; PATHOLOGY; PHYSIOLOGY; RETROVIRIDAE; RETROVIRUS INFECTION; SCID MOUSE; VIROLOGY; VIRUS LATENCY; VIRUS REPLICATION;

ANIMALS; DISEASE MODELS, ANIMAL; HOST-PATHOGEN INTERACTIONS; HUMANS; MICE, SCID; RETROVIRIDAE; RETROVIRIDAE INFECTIONS; VIRUS LATENCY; VIRUS REPLICATION;

EID: 84939783318     PISSN: 00426822     EISSN: 10960341     Source Type: Journal    
DOI: 10.1016/j.virol.2015.01.017     Document Type: Review

References (169)

1. Ahmad N., Venkatesan S. Nef protein of HIV-1 is a transcriptional repressor of HIV-1 LTR. Science 1988, 241:1481-1485.
2. Akkina R. New generation humanized mice for virus research: comparative aspects and future prospects. Virology 2013, 435:14-28.
3. Aldrovandi G.M., Feuer G., Gao L., Jamieson B., Kristeva M., Chen I.S., Zack J.A. The SCID-hu mouse as a model for HIV-1 infection. Nature 1993, 363:732-736.
4. Aldrovandi G.M., Gao L., Bristol G., Zack J.A. Regions of human immunodeficiency virus type 1 nef required for function in vivo. J. Virol. 1998, 72:7032-7039.
5. Aldrovandi G.M., Zack J.A. Replication and pathogenicity of human immunodeficiency virus type 1 accessory gene mutants in SCID-hu mice. J. Virol. 1996, 70:1505-1511.
6. Anthony I.C., Bell J.E. The neuropathology of HIV/AIDS. Int. Rev. Psychiatry 2008, 20:15-24.
7. Arlen P.A., Brooks D.G., Gao L.Y., Vatakis D., Brown H.J., Zack J.A. Rapid expression of human immunodeficiency virus following activation of latently infected cells. J. Virol. 2006, 80:1599-1603.
8. Balazs A.B., Bloom J.D., Hong C.M., Rao D.S., Baltimore D. Broad protection against influenza infection by vectored immunoprophylaxis in mice. Nat. Biotechnol. 2013, 31:647-652.
9. Balazs A.B., Chen J., Hong C.M., Rao D.S., Yang L., Baltimore D. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 2012, 481:81-84.
10. Balazs A.B., Ouyang Y., Hong C.M., Chen J., Nguyen S.M., Rao D.S., An D.S., Baltimore D. Vectored immunoprophylaxis protects humanized mice from mucosal HIV transmission. Nat. Med. 2014, 20:296-300.
11. Barre-Sinoussi F., Chermann J.C., Rey F., Nugeyre M.T., Chamaret S., Gruest J., Dauguet C., Axler-Blin C., Vezinet-Brun F., Rouzioux C., Rozenbaum W., Montagnier L. Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 1983, 220:868-871.
12. -/- (RAG-hu) mice. Virology 2008, 373:342-351.
13. -/- (RAG-hu) mouse model. Retrovirology 2006, 3:76.
14. Bieniasz P.D., Cullen B.R. Multiple blocks to human immunodeficiency virus type 1 replication in rodent cells. J. Virol. 2000, 74:9868-9877.
15. Blanc M., Hsieh W.Y., Robertson K.A., Watterson S., Shui G., Lacaze P., Khondoker M., Dickinson P., Sing G., Rodriguez-Martin S., Phelan P., Forster T., Strobl B., Muller M., Riemersma R., Osborne T., Wenk M.R., Angulo A., Ghazal P. Host defense against viral infection involves interferon mediated down-regulation of sterol biosynthesis. PLoS Biol. 2011, 9:e1000598.
16. Bonyhadi M.L., Rabin L., Salimi S., Brown D.A., Kosek J., McCune J.M., Kaneshima H. HIV induces thymus depletion in vivo. Nature 1993, 363:728-732.
17. Bosma G.C., Custer R.P., Bosma M.J. A severe combined immunodeficiency mutation in the mouse. Nature 1983, 301:527-530.
18. Brehm M.A., Cuthbert A., Yang C., Miller D.M., DiIorio P., Laning J., Burzenski L., Gott B., Foreman O., Kavirayani A., Herlihy M., Rossini A.A., Shultz L.D., Greiner D.L. Parameters for establishing humanized mouse models to study human immunity: analysis of human hematopoietic stem cell engraftment in three immunodeficient strains of mice bearing the IL2rgamma(null) mutation. Clin. Immunol. 2010, 135:84-98.
19. Brooks D.G., Arlen P.A., Gao L., Kitchen C.M., Zack J.A. Identification of T cell-signaling pathways that stimulate latent HIV in primary cells. Proc. Natl. Acad. Sci. USA 2003, 100:12955-12960.
20. Brooks D.G., Hamer D.H., Arlen P.A., Gao L., Bristol G., Kitchen C.M., Berger E.A., Zack J.A. Molecular characterization, reactivation, and depletion of latent HIV. Immunity 2003, 19:413-423.
21. Brooks D.G., Kitchen S.G., Kitchen C.M., Scripture-Adams D.D., Zack J.A. Generation of HIV latency during thymopoiesis. Nat. Med. 2001, 7:459-464.
22. Brooks D.G., Zack J.A. Effect of latent human immunodeficiency virus infection on cell surface phenotype. J. Virol. 2002, 76:1673-1681.
23. Browning J., Horner J.W., Pettoello-Mantovani M., Raker C., Yurasov S., DePinho R.A., Goldstein H. Mice transgenic for human CD4 and CCR5 are susceptible to HIV infection. Proc. Natl. Acad. Sci. USA 1997, 94:14637-14641.
24. Calenda V., Chermann J.C. The effects of HIV on hematopoiesis. Eur. J. Haematol. 1992, 48:181-186.
25. Cao X., Shores E.W., Hu-Li J., Anver M.R., Kelsall B.L., Russell S.M., Drago J., Noguchi M., Grinberg A., Bloom E.T., et al. Defective lymphoid development in mice lacking expression of the common cytokine receptor gamma chain. Immunity 1995, 2:223-238.
26. Chang H., Biswas S., Tallarico A.S., Sarkis P.T., Geng S., Panditrao M.M., Zhu Q., Marasco W.A. Human B-cell ontogeny in humanized NOD/SCID gammac(null) mice generates a diverse yet auto/poly- and HIV-1-reactive antibody repertoire. Genes Immun. 2012, 13:399-410.
27. Choi J.G., Bharaj P., Abraham S., Ma H., Yi G., Ye C., Dang Y., Manjunath N., Wu H., Shankar P. Multiplexing seven miRNA-based shRNAs to suppress HIV replication. Mol. Ther.: J. Am. Soc. Gene Ther. 2015, 23:310-320.
28. Choudhary S.K., Archin N.M., Cheema M., Dahl N.P., Garcia J.V., Margolis D.M. Latent HIV-1 infection of resting CD4(+) T cells in the humanized Rag2(-)/(-) gammac(-)/(-) mouse. J. Virol. 2012, 86:114-120.
29. -/- mouse. J. Virol. 2009, 83:8254-8258.
30. Christianson S.W., Greiner D.L., Hesselton R.A., Leif J.H., Wagar E.J., Schweitzer I.B., Rajan T.V., Gott B., Roopenian D.C., Shultz L.D. Enhanced human CD4+ T cell engraftment in beta2-microglobulin-deficient NOD-scid mice. J. Immunol. 1997, 158:3578-3586.
31. Chun T.-W., Davey R.T., Engel D., Lane H.C., Fauci A.S. AIDS: re-emergence of HIV after stopping therapy. Nature 1999, 401:874-875.
32. Chun T.W., Carruth L., Finzi D., Shen X., DiGiuseppe J.A., Taylor H., Hermankova M., Chadwick K., Margolick J., Quinn T.C., Kuo Y.H., Brookmeyer R., Zeiger M.A., Barditch-Crovo P., Siliciano R.F. Quantification of latent tissue reservoirs and total body viral load in HIV-1 infection. Nature 1997, 387:183-188.
33. Chun T.W., Stuyver L., Mizell S.B., Ehler L.A., Mican J.A., Baseler M., Lloyd A.L., Nowak M.A., Fauci A.S. Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc. Natl. Acad. Sci. USA 1997, 94:13193-13197.
34. Danner R., Chaudhari S.N., Rosenberger J., Surls J., Richie T.L., Brumeanu T.D., Casares S. Expression of HLA class II molecules in humanized NOD.Rag1KO.IL2RgcKO mice is critical for development and function of human T and B cells. PloS One 2011, 6:e19826.
35. Dash P.K., Gendelman H.E., Roy U., Balkundi S., Alnouti Y., Mosley R.L., Gelbard H.A., McMillan J., Gorantla S., Poluektova L.Y. Long-acting nanoformulated antiretroviral therapy elicits potent antiretroviral and neuroprotective responses in HIV-1-infected humanized mice. AIDS 2012, 26:2135-2144.
36. Deacon N.J., Tsykin A., Solomon A., Smith K., Ludford-Menting M., Hooker D.J., McPhee D.A., Greenway A.L., Ellett A., Chatfield C., Lawson V.A., Crowe S., Maerz A., Sonza S., Learmont J., Sullivan J.S., Cunningham A., Dwyer D., Dowton D., Mills J. Genomic structure of an attenuated quasi species of HIV-1 from a blood transfusion donor and recipients. Science 1995, 270:988-991.
37. Deal C., Balazs A.B., Espinosa D.A., Zavala F., Baltimore D., Ketner G. Vectored antibody gene delivery protects against Plasmodium falciparum sporozoite challenge in mice. Proc. Natl. Acad. Sci. USA 2014, 111:12528-12532.
38. Denton P.W., Estes J.D., Sun Z., Othieno F.A., Wei B.L., Wege A.K., Powell D.A., Payne D., Haase A.T., Garcia J.V. Antiretroviral pre-exposure prophylaxis prevents vaginal transmission of HIV-1 in humanized BLT mice. PLoS Med. 2008, 5:e16.
39. Denton P.W., Krisko J.F., Powell D.A., Mathias M., Kwak Y.T., Martinez-Torres F., Zou W., Payne D.A., Estes J.D., Garcia J.V. Systemic administration of antiretrovirals prior to exposure prevents rectal and intravenous HIV-1 transmission in humanized BLT mice. PloS One 2010, 5:e8829.
40. Denton P.W., Long J.M., Wietgrefe S.W., Sykes C., Spagnuolo R.A., Snyder O.D., Perkey K., Archin N.M., Choudhary S.K., Yang K., Hudgens M.G., Pastan I., Haase A.T., Kashuba A.D., Berger E.A., Margolis D.M., Garcia J.V. Targeted cytotoxic therapy kills persisting HIV infected cells during ART. PLoS Pathog. 2014, 10:e1003872.
41. Denton P.W., Olesen R., Choudhary S.K., Archin N.M., Wahl A., Swanson M.D., Chateau M., Nochi T., Krisko J.F., Spagnuolo R.A., Margolis D.M., Garcia J.V. Generation of HIV latency in humanized BLT mice. J. Virol. 2012, 86:630-634.
42. Denton P.W., Othieno F., Martinez-Torres F., Zou W., Krisko J.F., Fleming E., Zein S., Powell D.A., Wahl A., Kwak Y.T., Welch B.D., Kay M.S., Payne D.A., Gallay P., Appella E., Estes J.D., Lu M., Garcia J.V. One percent tenofovir applied topically to humanized BLT mice and used according to the CAPRISA 004 experimental design demonstrates partial protection from vaginal HIV infection, validating the BLT model for evaluation of new microbicide candidates. J. Virol. 2011, 85:7582-7593.
43. Di Fabio S., Giannini G., Lapenta C., Spada M., Binelli A., Germinario E., Sestili P., Belardelli F., Proietti E., Vella S. Vaginal transmission of HIV-1 in hu-SCID mice: a new model for the evaluation of vaginal microbicides. AIDS 2001, 15:2231-2238.
44. DiSanto J.P., Muller W., Guy-Grand D., Fischer A., Rajewsky K. Lymphoid development in mice with a targeted deletion of the interleukin 2 receptor gamma chain. Proc. Natl. Acad. Sci. USA 1995, 92:377-381.
45. Dodon M.D., Villaudy J., Gazzolo L., Haines R., Lairmore M. What we are learning on HTLV-1 pathogenesis from animal models. Front. Microbiol. 2012, 3:320.
46. Dudek T.E., No D.C., Seung E., Vrbanac V.D., Fadda L., Bhoumik P., Boutwell C.L., Power K.A., Gladden A.D., Battis L., Mellors E.F., Tivey T.R., Gao X., Altfeld M., Luster A.D., Tager A.M., Allen T.M. Rapid evolution of HIV-1 to functional CD8(+) T cell responses in humanized BLT mice. Sci. Transl. Med. 2012, 4:143ra198.
47. Feuer G., Stewart S.A., Baird S.M., Lee F., Feuer R., Chen I.S. Potential role of natural killer cells in controlling tumorigenesis by human T-cell leukemia viruses. J. Virol. 1995, 69:1328-1333.
48. Feuer G., Zack J.A., Harrington W.J., Valderama R., Rosenblatt J.D., Wachsman W., Baird S.M., Chen I.S. Establishment of human T-cell leukemia virus type I T-cell lymphomas in severe combined immunodeficient mice. Blood 1993, 82:722-731.
49. Finzi D., Blankson J., Siliciano J.D., Margolick J.B., Chadwick K., Pierson T., Smith K., Lisziewicz J., Lori F., Flexner C., Quinn T.C., Chaisson R.E., Rosenberg E., Walker B., Gange S., Gallant J., Siliciano R.F. Latent infection of CD4+ T cells provides a mechanism for lifelong persistence of HIV-1, even in patients on effective combination therapy. Nat. Med. 1999, 5:512-517.
50. Flanagan S.P. 'Nude', a new hairless gene with pleiotropic effects in the mouse. Genet. Res. 1966, 8:295-309.
51. Fu X.Y., Besterman J.M., Monosov A., Hoffman R.M. Models of human metastatic colon cancer in nude mice orthotopically constructed by using histologically intact patient specimens. Proc. Natl. Acad. Sci. USA 1991, 88:9345-9349.
52. Gallo R.C., Sarin P.S., Gelmann E.P., Robert-Guroff M., Richardson E., Kalyanaraman V.S., Mann D., Sidhu G.D., Stahl R.E., Zolla-Pazner S., Leibowitch J., Popovic M. Isolation of human T-cell leukemia virus in acquired immune deficiency syndrome (AIDS). Science 1983, 220:865-867.
53. Gardner M.B., Luciw P.A. Macaque models of human infectious disease. ILAR J. 2008, 49:220-255.
54. Gauduin M.C., Parren P.W., Weir R., Barbas C.F., Burton D.R., Koup R.A. Passive immunization with a human monoclonal antibody protects hu-PBL-SCID mice against challenge by primary isolates of HIV-1. Nat. Med. 1997, 3:1389-1393.
55. Gulizia R.J., Collman R.G., Levy J.A., Trono D., Mosier D.E. Deletion of nef slows but does not prevent CD4-positive T-cell depletion in human immunodeficiency virus type 1-infected human-PBL-SCID mice. J. Virol. 1997, 71:4161-4164.
56. Halper-Stromberg A., Lu C.L., Klein F., Horwitz J.A., Bournazos S., Nogueira L., Eisenreich T.R., Liu C., Gazumyan A., Schaefer U., Furze R.C., Seaman M.S., Prinjha R., Tarakhovsky A., Ravetch J.V., Nussenzweig M.C. Broadly neutralizing antibodies and viral inducers decrease rebound from HIV-1 latent reservoirs in humanized mice. Cell 2014, 158:989-999.
57. Hanna Z., Kay D.G., Rebai N., Guimond A., Jothy S., Jolicoeur P. Nef harbors a major determinant of pathogenicity for an AIDS-like disease induced by HIV-1 in transgenic mice. Cell 1998, 95:163-175.
58. Hatziioannou T., Evans D.T. Animal models for HIV/AIDS research. Nat. Rev. Microbiol. 2012, 10:852-867.
59. Hayakawa J., Hsieh M.M., Uchida N., Phang O., Tisdale J.F. Busulfan produces efficient human cell engraftment in NOD/LtSz-Scid IL2Rgamma(null) mice. Stem Cells 2009, 27:175-182.
60. Hesselton R.M., Greiner D.L., Mordes J.P., Rajan T.V., Sullivan J.L., Shultz L.D. High levels of human peripheral blood mononuclear cell engraftment and enhanced susceptibility to human immunodeficiency virus type 1 infection in NOD/LtSz-scid/scid mice. J. Infect. Dis. 172 1995, 974-982.
61. Hirsch V.M., Olmsted R.A., Murphey-Corb M., Purcell R.H., Johnson P.R. An African primate lentivirus (SIVsm) closely related to HIV-2. Nature 1989, 339:389-392.
62. Ho Y.C., Shan L., Hosmane N.N., Wang J., Laskey S.B., Rosenbloom D.I., Lai J., Blankson J.N., Siliciano J.D., Siliciano R.F. Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 2013, 155:540-551.
63. Holt N., Wang J., Kim K., Friedman G., Wang X., Taupin V., Crooks G.M., Kohn D.B., Gregory P.D., Holmes M.C., Cannon P.M. Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo. Nat Biotechnol 2010, 28:839-847.
64. Honeycutt J.B., Sheridan P.A., Matsushima G.K., Garcia J.V. Humanized mouse models for HIV-1 infection of the CNS. J. Neurovirol. 2014, (Epub ahead of print). 10.1007/s13365-014-0299-6.
65. Honeycutt J.B., Wahl A., Archin N., Choudhary S., Margolis D., Garcia J.V. HIV-1 infection, response to treatment and establishment of viral latency in a novel humanized T cell-only mouse (TOM) model. Retrovirology 2013, 10:121.
66. Hutter G., Nowak D., Mossner M., Ganepola S., Mussig A., Allers K., Schneider T., Hofmann J., Kucherer C., Blau O., Blau I.W., Hofmann W.K., Thiel E. Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 2009, 360:692-698.
67. Imada K., Takaori-Kondo A., Akagi T., Shimotohno K., Sugamura K., Hattori T., Yamabe H., Okuma M., Uchiyama T. Tumorigenicity of human T-cell leukemia virus type I-infected cell lines in severe combined immunodeficient mice and characterization of the cells proliferating in vivo. Blood 1995, 86:2350-2357.
68. -/- humanized mouse model. J. Virol. 2010, 84:2740-2752.
69. Ishikawa F., Yasukawa M., Lyons B., Yoshida S., Miyamoto T., Yoshimoto G., Watanabe T., Akashi K., Shultz L.D., Harada M. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain(null) mice. Blood 2005, 106:1565-1573.
70. Ito R., Takahashi T., Katano I., Ito M. Current advances in humanized mouse models. Cell. Mol. Immunol. 2012, 9:208-214.
71. Jacobs H., Krimpenfort P., Haks M., Allen J., Blom B., Demolliere C., Kruisbeek A., Spits H., Berns A. PIM1 reconstitutes thymus cellularity in interleukin 7- and common gamma chain-mutant mice and permits thymocyte maturation in Rag- but not CD3gamma-deficient mice. J. Exp. Med. 1999, 190:1059-1068.
72. Jamieson B.D., Aldrovandi G.M., Planelles V., Jowett J.B., Gao L., Bloch L.M., Chen I.S., Zack J.A. Requirement of human immunodeficiency virus type 1 nef for in vivo replication and pathogenicity. J. Virol. 1994, 68:3478-3485.
73. Jamieson B.D., Aldrovandi G.M., Zack J.A. The SCID-hu mouse: an in-vivo model for HIV-1 pathogenesis and stem cell gene therapy for AIDS. Semin. Immunol. 1996, 8:215-221.
74. Jamieson B.D., Pang S., Aldrovandi G.M., Zha J., Zack J.A. In vivo pathogenic properties of two clonal human immunodeficiency virus type 1 isolates. J. Virol. 1995, 69:6259-6264.
75. Jenkins M., Hanley M.B., Moreno M.B., Wieder E., McCune J.M. Human immunodeficiency virus-1 infection interrupts thymopoiesis and multilineage hematopoiesis in vivo. Blood 1998, 91:2672-2678.
76. Kalscheuer H., Danzl N., Onoe T., Faust T., Winchester R., Goland R., Greenberg E., Spitzer T.R., Savage D.G., Tahara H., Choi G., Yang Y.G., Sykes M. A model for personalized in vivo analysis of human immune responsiveness. Sci. Transl. Med.. 125ra130 2012, 4.
77. Kaneshima H., Shih C.C., Namikawa R., Rabin L., Outzen H., Machado S.G., McCune J.M. Human immunodeficiency virus infection of human lymph nodes in the SCID-hu mouse. Proc. Natl. Acad. Sci. USA 1991, 88:4523-4527.
78. Keele B.F., Jones J.H., Terio K.A., Estes J.D., Rudicell R.S., Wilson M.L., Li Y., Learn G.H., Beasley T.M., Schumacher-Stankey J., Wroblewski E., Mosser A., Raphael J., Kamenya S., Lonsdorf E.V., Travis D.A., Mlengeya T., Kinsel M.J., Else J.G., Silvestri G., Goodall J., Sharp P.M., Shaw G.M., Pusey A.E., Hahn B.H. Increased mortality and AIDS-like immunopathology in wild chimpanzees infected with SIVcpz. Nature 2009, 460:515-519.
79. Keele B.F., Van Heuverswyn F., Li Y., Bailes E., Takehisa J., Santiago M.L., Bibollet-Ruche F., Chen Y., Wain L.V., Liegeois F., Loul S., Ngole E.M., Bienvenue Y., Delaporte E., Brookfield J.F., Sharp P.M., Shaw G.M., Peeters M., Hahn B.H. Chimpanzee reservoirs of pandemic and nonpandemic HIV-1. Science 2006, 313:523-526.
80. Kennedy M.K., Glaccum M., Brown S.N., Butz E.A., Viney J.L., Embers M., Matsuki N., Charrier K., Sedger L., Willis C.R., Brasel K., Morrissey P.J., Stocking K., Schuh J.C., Joyce S., Peschon J.J. Reversible defects in natural killer and memory CD8 T cell lineages in interleukin 15-deficient mice. J. Exp. Med. 2000, 191:771-780.
81. King M., Pearson T., Shultz L.D., Leif J., Bottino R., Trucco M., Atkinson M.A., Wasserfall C., Herold K.C., Woodland R.T., Schmidt M.R., Woda B.A., Thompson M.J., Rossini A.A., Greiner D.L. A new Hu-PBL model for the study of human islet alloreactivity based on NOD-scid mice bearing a targeted mutation in the IL-2 receptor gamma chain gene. Clin. Immunol. 2008, 126:303-314.
82. King M.A., Covassin L., Brehm M.A., Racki W., Pearson T., Leif J., Laning J., Fodor W., Foreman O., Burzenski L., Chase T.H., Gott B., Rossini A.A., Bortell R., Shultz L.D., Greiner D.L. Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complex. Clin. Exp. Immunol. 2009, 157:104-118.
83. Kirchhoff F., Hunsmann G. The negative (?) factor of HIV and SIV. Res. Virol. 1992, 143:66-69.
84. Kitchen S.G., Killian S., Giorgi J.V., Zack J.A. Functional reconstitution of thymopoiesis after human immunodeficiency virus infection. J. Virol. 2000, 74:2943-2948.
85. Kitchen S.G., Levin B.R., Bristol G., Rezek V., Kim S., Aguilera-Sandoval C., Balamurugan A., Yang O.O., Zack J.A. In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog. 2012, 8:e1002649.
86. Koka P.S., Brooks D.G., Razai A., Kitchen C.M., Zack J.A. HIV type 1 infection alters cytokine mRNA expression in thymus. AIDS Res. Hum. Retrovir. 2003, 19:1-12.
87. Koka P.S., Fraser J.K., Bryson Y., Bristol G.C., Aldrovandi G.M., Daar E.S., Zack J.A. Human immunodeficiency virus inhibits multilineage hematopoiesis in vivo. J. Virol. 1998, 72:5121-5127.
88. Koka P.S., Jamieson B.D., Brooks D.G., Zack J.A. Human immunodeficiency virus type 1-induced hematopoietic inhibition is independent of productive infection of progenitor cells in vivo. J. Virol. 1999, 73:9089-9097.
89. Kollmann T.R., Pettoello-Mantovani M., Zhuang X., Kim A., Hachamovitch M., Smarnworawong P., Rubinstein A., Goldstein H. Disseminated human immunodeficiency virus 1 (HIV-1) infection in SCID-hu mice after peripheral inoculation with HIV-1. J. Exp. Med. 1994, 179:513-522.
90. Kondo A., Imada K., Hattori T., Yamabe H., Tanaka T., Miyasaka M., Okuma M., Uchiyama T. A model of in vivo cell proliferation of adult T-cell leukemia. Blood 1993, 82:2501-2509.
91. Korin Y.D., Brooks D.G., Brown S., Korotzer A., Zack J.A. Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J. Virol. 2002, 76:8118-8123.
92. Kovochich M., Marsden M.D., Zack J.A. Activation of latent HIV using drug-loaded nanoparticles. PLoS One 2011, 6:e18270.
93. Kumar P., Ban H.S., Kim S.S., Wu H., Pearson T., Greiner D.L., Laouar A., Yao J., Haridas V., Habiro K., Yang Y.G., Jeong J.H., Lee K.Y., Kim Y.H., Kim S.W., Peipp M., Fey G.H., Manjunath N., Shultz L.D., Lee S.K., Shankar P. T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice. Cell 2008, 134:577-586.
94. Lan P., Tonomura N., Shimizu A., Wang S., Yang Y.G. Reconstitution of a functional human immune system in immunodeficient mice through combined human fetal thymus/liver and CD34+ cell transplantation. Blood 2006, 108:487-492.
95. Lapidot T., Pflumio F., Doedens M., Murdoch B., Williams D.E., Dick J.E. Cytokine stimulation of multilineage hematopoiesis from immature human cells engrafted in SCID mice. Science 1992, 255:1137-1141.
96. -/- mice are resistant to GVHD and develop B- and T-cell immunity to HIV infection. Blood 2013, 122:4013-4020.
97. Leonard J.M., Abramczuk J.W., Pezen D.S., Rutledge R., Belcher J.H., Hakim F., Shearer G., Lamperth L., Travis W., Fredrickson T., et al. Development of disease and virus recovery in transgenic mice containing HIV proviral DNA. Science 1988, 242:1665-1670.
98. -/-, and C.B-17-scid/bg immunodeficient mice. Hum. Immunol. 2009, 70:790-802.
99. Letvin N.L., Daniel M.D., Sehgal P.K., Desrosiers R.C., Hunt R.D., Waldron L.M., MacKey J.J., Schmidt D.K., Chalifoux L.V., King N.W. Induction of AIDS-like disease in macaque monkeys with T-cell tropic retrovirus STLV-III. Science 1985, 230:71-73.
100. Liu S.Y., Aliyari R., Chikere K., Li G., Marsden M.D., Smith J.K., Pernet O., Guo H., Nusbaum R., Zack J.A., Freiberg A.N., Su L., Lee B., Cheng G. Interferon-inducible cholesterol-25-hydroxylase broadly inhibits viral entry by production of 25-hydroxycholesterol. Immunity 2013, 38:92-105.
101. Liu Y., Dole K., Stanley J.R., Richard V., Rosol T.J., Ratner L., Lairmore M., Feuer G. Engraftment and tumorigenesis of HTLV-1 transformed T cell lines in SCID/bg and NOD/SCID mice. Leuk. Res. 2002, 26:561-567.
102. Luciw P.A., Cheng-Mayer C., Levy J.A. Mutational analysis of the human immunodeficiency virus: the orf-B region down-regulates virus replication. Proc. Natl. Acad. Sci. USA 1987, 84:1434-1438.
103. Mahieux R., Gessain A. HTLV-3/STLV-3 and HTLV-4 viruses: discovery, epidemiology, serology and molecular aspects. Viruses 2011, 3:1074-1090.
104. Manz M.G. Human-hemato-lymphoid-system mice: opportunities and challenges. Immunity 2007, 26:537-541.
105. Marsden M.D., Kovochich M., Suree N., Shimizu S., Mehta R., Cortado R., Bristol G., Zack D.S. HIV latency in the humanized BLT mouse. J. Virol. 2012, 86:339-347.
106. Marsden M.D., Zack J.A. Human immunodeficiency virus bearing a disrupted central DNA flap is pathogenic in vivo. J. Virol. 2007, 81:6146-6150.
107. Marsden M.D., Zack J.A. Establishment and maintenance of HIV latency: model systems and opportunities for intervention. Fut. Virol. 2010, 5:97-109.
108. Marsden M.D., Zack J.A. HIV/AIDS eradication. Bioorg. Med. Chem. Lett. 2013, 23:4003-4010.
109. Marsden M.D., Zack J.A. Neutralizing the HIV reservoir. Cell 2014, 158:971-972.
110. McCune J.M., Namikawa R., Kaneshima H., Shultz L.D., Lieberman M., Weissman I.L. The SCID-hu mouse: murine model for the analysis of human hematolymphoid differentiation and function. Science 1988, 241:1632-1639.
111. McCune J.M., Kaneshima H., Rabin L., Shih C.C., Namikawa R. Preclinical evaluation of antiviral compounds in the SCID-hu mouse. Ann. N. Y. Acad. Sci. 1990, 616:281-286.
112. McCune J.M., Namikawa R., Shih C.C., Rabin L., Kaneshima H. Suppression of HIV infection in AZT-treated SCID-hu mice. Science 1990, 247:564-566.
113. Meiering C.D., Linial M.L. Historical perspective of foamy virus epidemiology and infection. Clin. Microbiol. Rev. 2001, 14:165-176.
114. Melkus M.W., Estes J.D., Padgett-Thomas A., Gatlin J., Denton P.W., Othieno F.A., Wege A.K., Haase A.T., Garcia J.V. Humanized mice mount specific adaptive and innate immune responses to EBV and TSST-1. Nat. Med. 2006, 12:1316-1322.
115. Miyazato P., Yasunaga J., Taniguchi Y., Koyanagi Y., Mitsuya H., Matsuoka M. De novo human T-cell leukemia virus type 1 infection of human lymphocytes in NOD-SCID, common gamma-chain knockout mice. J. Virol. 2006, 80:10683-10691.
116. Miyoshi H., Smith K.A., Mosier D.E., Verma I.M., Torbett B.E. Transduction of human CD34+ cells that mediate long-term engraftment of NOD/SCID mice by HIV vectors. Science 1999, 283:682-686.
117. Mombaerts P., Iacomini J., Johnson R.S., Herrup K., Tonegawa S., Papaioannou V.E. RAG-1-deficient mice have no mature B and T lymphocytes. Cell 1992, 68:869-877.
118. Morrow W.J., Wharton M., Lau D., Levy J.A. Small animals are not susceptible to human immunodeficiency virus infection. J. Gen. Virol. 1987, 68:2253-2257.
119. Mosier D.E., Gulizia R.J., Baird S.M., Wilson D.B. Transfer of a functional human immune system to mice with severe combined immunodeficiency. Nature 1988, 335:256-259.
120. Mosier D.E., Gulizia R.J., Baird S.M., Wilson D.B., Spector D.H., Spector S.A. Human immunodeficiency virus infection of human-PBL-SCID mice. Science 1991, 251:791-794.
121. Mosier D.E., Gulizia R.J., MacIsaac P.D., Torbett B.E., Levy J.A. Rapid loss of CD4+ T cells in human-PBL-SCID mice by noncytopathic HIV isolates. Science 1993, 260:689-692.
122. Namikawa R., Kaneshima H., Lieberman M., Weissman I.L., McCune J.M. Infection of the SCID-hu mouse by HIV-1. Science 1988, 242:1684-1686.
123. Namikawa R., Weilbaecher K.N., Kaneshima H., Yee E.J., McCune J.M. Long-term human hematopoiesis in the SCID-hu mouse. J. Exp. Med. 1990, 172:1055-1063.
124. Neff C.P., Zhou J., Remling L., Kuruvilla J., Zhang J., Li H., Smith D.D., Swiderski P., Rossi J.J., Akkina R. An aptamer-siRNA chimera suppresses HIV-1 viral loads and protects from helper CD4(+) T cell decline in humanized mice. Sci. Transl. Med.. 66ra66 2011, 3.
125. Nehls M., Pfeifer D., Schorpp M., Hedrich H., Boehm T. New member of the winged-helix protein family disrupted in mouse and rat nude mutations. Nature 1994, 372:103-107.
126. Nixon C.C., Vatakis D.N., Reichelderfer S.N., Dixit D., Kim S.G., Uittenbogaart C.H., Zack J.A. HIV-1 infection of hematopoietic progenitor cells in vivo in humanized mice. Blood 2013, 122:2195-2204.
127. Ohbo K., Suda T., Hashiyama M., Mantani A., Ikebe M., Miyakawa K., Moriyama M., Nakamura M., Katsuki M., Takahashi K., Yamamura K., Sugamura K. Modulation of hematopoiesis in mice with a truncated mutant of the interleukin-2 receptor gamma chain. Blood 1996, 87:956-967.
128. Parren P.W., Ditzel H.J., Gulizia R.J., Binley J.M., Barbas C.F., Burton D.R., Mosier D.E. Protection against HIV-1 infection in hu-PBL-SCID mice by passive immunization with a neutralizing human monoclonal antibody against the gp120 CD4-binding site. AIDS 1995, 9:F1-F6.
129. Perez E.E., Wang J., Miller J.C., Jouvenot Y., Kim K.A., Liu O., Wang N., Lee G., Bartsevich V.V., Lee Y.L., Guschin D.Y., Rupniewski I., Waite A.J., Carpenito C., Carroll R.G., Orange J.S., Urnov F.D., Rebar E.J., Ando D., Gregory P.D., Riley J.L., Holmes M.C., June C.H. Establishment of HIV-1 resistance in CD4+ T cells by genome editing using zinc-finger nucleases. Nat. Biotechnol. 2008, 26:808-816.
130. Proietti F.A., Carneiro-Proietti A.B., Catalan-Soares B.C., Murphy E.L. Global epidemiology of HTLV-I infection and associated diseases. Oncogene 2005, 24:6058-6068.
131. Qin X.F., An D.S., Chen I.S., Baltimore D. Inhibiting HIV-1 infection in human T cells by lentiviral-mediated delivery of small interfering RNA against CCR5. Proc. Natl. Acad. Sci. USA 2003, 100:183-188.
132. Ranson T., Vosshenrich C.A., Corcuff E., Richard O., Muller W., Di Santo J.P. IL-15 is an essential mediator of peripheral NK-cell homeostasis. Blood 2003, 101:4887-4893.
133. Rathinam C., Poueymirou W.T., Rojas J., Murphy A.J., Valenzuela D.M., Yancopoulos G.D., Rongvaux A., Eynon E.E., Manz M.G., Flavell R.A. Efficient differentiation and function of human macrophages in humanized CSF-1 mice. Blood 2011, 118:3119-3128.
134. Reeves J.D., Doms R.W. Human immunodeficiency virus type 2. J. Gen. Virol. 2002, 83:1253-1265.
135. Ringpis G.E., Shimizu S., Arokium H., Camba-Colon J., Carroll M.V., Cortado R., Xie Y., Kim P.Y., Sahakyan A., Lowe E.L., Narukawa M., Kandarian F.N., Burke B.P., Symonds G.P., An D.S., Chen I.S., Kamata M. Engineering HIV-1-resistant T-cells from short-hairpin RNA-expressing hematopoietic stem/progenitor cells in humanized BLT mice. PloS One 2012, 7:e53492.
136. Rizza P., Santini S.M., Logozzi M.A., Lapenta C., Sestili P., Gherardi G., Lande R., Spada M., Parlato S., Belardelli F., Fais S. T-cell dysfunctions in hu-PBL-SCID mice infected with human immunodeficiency virus (HIV) shortly after reconstitution: in vivo effects of HIV on highly activated human immune cells. J. Virol. 1996, 70:7958-7964.
137. Safrit J.T., Fung M.S., Andrews C.A., Braun D.G., Sun W.N., Chang T.W., Koup R.A. hu-PBL-SCID mice can be protected from HIV-1 infection by passive transfer of monoclonal antibody to the principal neutralizing determinant of envelope gp120. AIDS 1993, 7:15-21.
138. *57 elite suppressor and chronic progressor HIV-1 isolates replicate vigorously and cause CD4+ T cell depletion in humanized BLT mice. J. Virol. 2014, 88:3340-3352.
139. Scripture-Adams D.D., Brooks D.G., Korin Y.D., Zack J.A. Interleukin-7 induces expression of latent human immunodeficiency virus type 1 with minimal effects on T-cell phenotype. J. Virol. 2002, 76:13077-13082.
140. Sharp P.M., Hahn B.H. Origins of HIV and the AIDS pandemic. Cold Spring. Harb. Perspect. Med. 2011, 1:a006841.
141. Shimizu S., Hong P., Arumugam B., Pokomo L., Boyer J., Koizumi N., Kittipongdaja P., Chen A., Bristol G., Galic Z., Zack J.A., Yang O., Chen I.S., Lee B., An D.S. A highly efficient short hairpin RNA potently down-regulates CCR5 expression in systemic lymphoid organs in the hu-BLT mouse model. Blood 2010, 115:1534-1544.
142. Shinkai Y., Rathbun G., Lam K.P., Oltz E.M., Stewart V., Mendelsohn M., Charron J., Datta M., Young F., Stall A.M., et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V(D)J rearrangement. Cell 1992, 68:855-867.
143. Shultz L.D., Brehm M.A., Garcia-Martinez J.V., Greiner D.L. Humanized mice for immune system investigation: progress, promise and challenges. Nat. Rev. Immunol. 2012, 12:786-798.
144. Shultz L.D., Ishikawa F., Greiner D.L. Humanized mice in translational biomedical research. Nat. Rev. Immunol. 2007, 7:118-130.
145. Shultz L.D., Schweitzer P.A., Christianson S.W., Gott B., Schweitzer I.B., Tennent B., McKenna S., Mobraaten L., Rajan T.V., Greiner D.L., et al. Multiple defects in innate and adaptive immunologic function in NOD/LtSz-scid mice. J. Immunol. 1995, 154:180-191.
146. Stevenson M., Stanwick T.L., Dempsey M.P., Lamonica C.A. HIV-1 replication is controlled at the level of T cell activation and proviral integration. EMBO J. 1990, 9:1551-1560.
147. Stewart S.A., Feuer G., Jewett A., Lee F.V., Bonavida B., Chen I.S. HTLV-1 gene expression in adult T-cell leukemia cells elicits an NK cell response in vitro and correlates with cell rejection in SCID mice. Virology 1996, 226:167-175.
148. Stoddart C.A., Geleziunas R., Ferrell S., Linquist-Stepps V., Moreno M.E., Bare C., Xu W., Yonemoto W., Bresnahan P.A., McCune J.M., Greene W.C. Human immunodeficiency virus type 1 Nef-mediated downregulation of CD4 correlates with Nef enhancement of viral pathogenesis. J. Virol. 2003, 77:2124-2133.
149. Stoddart C.A., Joshi P., Sloan B., Bare J.C., Smith P.C., Allaway G.P., Wild C.T., Martin D.E. Potent activity of the HIV-1 maturation inhibitor bevirimat in SCID-hu Thy/Liv mice. PloS One 2007, 2:e1251.
150. Stoddart C.A., Liegler T.J., Mammano F., Linquist-Stepps V.D., Hayden M.S., Deeks S.G., Grant R.M., Clavel F., McCune J.M. Impaired replication of protease inhibitor-resistant HIV-1 in human thymus. Nat. Med. 2001, 7:712-718.
151. Stoddart C.A., Maidji E., Galkina S.A., Kosikova G., Rivera J.M., Moreno M.E., Sloan B., Joshi P., Long B.R. Superior human leukocyte reconstitution and susceptibility to vaginal HIV transmission in humanized NOD-scid IL-2Rgamma(-/-) (NSG) BLT mice. Virology 2011, 417:154-160.
152. Stoddart C.A., Nault G., Galkina S.A., Bousquet-Gagnon N., Bridon D., Quraishi O. Preexposure prophylaxis with albumin-conjugated C34 peptide HIV-1 fusion inhibitor in SCID-hu Thy/Liv mice. Antimicrob. Agents Chemother. 2012, 56:2162-2165.
153. Sun J., Zheng J.H., Zhao M., Lee S., Goldstein H. Increased in vivo activation of microglia and astrocytes in the brains of mice transgenic for an infectious R5 human immunodeficiency virus type 1 provirus and for CD4-specific expression of human cyclin T1 in response to stimulation by lipopolysaccharides. J. Virol. 2008, 82:5562-5572.
154. Tezuka K., Xun R., Tei M., Ueno T., Tanaka M., Takenouchi N., Fujisawa J. An animal model of adult T-cell leukemia: humanized mice with HTLV-1-specific immunity. Blood 2014, 123:346-355.
155. Traggiai E., Chicha L., Mazzucchelli L., Bronz L., Piffaretti J.C., Lanzavecchia A., Manz M.G. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science 2004, 304:104-107.
156. UNAIDS, 2013. UNAIDS Report on the Global AIDS Epidemic.
157. Wahl A., Swanson M.D., Nochi T., Olesen R., Denton P.W., Chateau M., Garcia J.V. Human breast milk and antiretrovirals dramatically reduce oral HIV-1 transmission in BLT humanized mice. PLoS Pathog. 2012, 8:e1002732.
158. Watanabe S., Terashima K., Ohta S., Horibata S., Yajima M., Shiozawa Y., Dewan M.Z., Yu Z., Ito M., Morio T., Shimizu N., Honda M., Yamamoto N. Hematopoietic stem cell-engrafted NOD/SCID/IL2Rgamma null mice develop human lymphoid systems and induce long-lasting HIV-1 infection with specific humoral immune responses. Blood 2007, 109:212-218.
159. Weiss R.A. Retrovirus classification and cell interactions. J. Antimicrob. Chemother. 1996, 37(Suppl. B):1-11.
160. WHO, 2014. World Health Organization: World Health Statistics Report.
161. Wilen C.B., Wang J., Tilton J.C., Miller J.C., Kim K.A., Rebar E.J., Sherrill-Mix S.A., Patro S.C., Secreto A.J., Jordan A.P., Lee G., Kahn J., Aye P.P., Bunnell B.A., Lackner A.A., Hoxie J.A., Danet-Desnoyers G.A., Bushman F.D., Riley J.L., Gregory P.D., June C.H., Holmes M.C., Doms R.W. Engineering HIV-resistant human CD4+ T cells with CXCR4-specific zinc-finger nucleases. PLoS Pathog. 2011, 7:e1002020.
162. Willinger T., Rongvaux A., Takizawa H., Yancopoulos G.D., Valenzuela D.M., Murphy A.J., Auerbach W., Eynon E.E., Stevens S., Manz M.G., Flavell R.A. Human IL-3/GM-CSF knock-in mice support human alveolar macrophage development and human immune responses in the lung. Proc. Natl. Acad. Sci. USA 2011, 108:2390-2395.
163. Withers-Ward E.S., Amado R.G., Koka P.S., Jamieson B.D., Kaplan A.H., Chen I.S., Zack J.A. Transient renewal of thymopoiesis in HIV-infected human thymic implants following antiviral therapy. Nat. Med. 1997, 3:1102-1109.
164. Worobey M., Gemmel M., Teuwen D.E., Haselkorn T., Kunstman K., Bunce M., Muyembe J.J., Kabongo J.M., Kalengayi R.M., Van Marck E., Gilbert M.T., Wolinsky S.M. Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature 2008, 455:661-664.
165. Yuan J., Wang J., Crain K., Fearns C., Kim K.A., Hua K.L., Gregory P.D., Holmes M.C., Torbett B.E. Zinc-finger nuclease editing of human cxcr4 promotes HIV-1 CD4(+) T cell resistance and enrichment. Mol. Ther.: J. Am. Soc. Gene Ther. 2012, 20:849-859.
166. Zack J.A., Arrigo S.J., Weitsman S.R., Go A.S., Haislip A., Chen I.S. HIV-1 entry into quiescent primary lymphocytes: molecular analysis reveals a labile, latent viral structure. Cell 1990, 61:213-222.
167. Zhang L., Kovalev G.I., Su L. HIV-1 infection and pathogenesis in a novel humanized mouse model. Blood 2007, 109:2978-2981.
168. Zhou J., Neff C.P., Liu X., Zhang J., Li H., Smith D.D., Swiderski P., Aboellail T., Huang Y., Du Q., Liang Z., Peng L., Akkina R., Rossi J.J. Systemic administration of combinatorial dsiRNAs via nanoparticles efficiently suppresses HIV-1 infection in humanized mice. Mol. Ther.: J. Am. Soc. Gene Ther. 2011, 19:2228-2238.
169. Zou W., Denton P.W., Watkins R.L., Krisko J.F., Nochi T., Foster J.L., Garcia J.V. Nef functions in BLT mice to enhance HIV-1 replication and deplete CD4+CD8+ thymocytes. Retrovirology 2012, 9:44.